PRP38 domain containing A pseudogene 1Genealiases: []
Q-omics provides the consensus-scored PRPF38AP1 profile across patient tissues and cancer cell-line models. PRPF38AP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, PRPF38AP1 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, PRPF38AP1 RNA expression shows 6,372 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, LIHC, and STAD as cancer lineages where PRPF38AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF38AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF38AP1 survival associations across molecular data types. PRPF38AP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF38AP1 RNA expression–survival associations across cancer types. High PRPF38AP1 expression shows unfavorable associations in THYM, ACC and DLBC, but favorable associations in STAD, COAD and KIRP. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for PRPF38AP1 RNA expression.
This table summarizes PRPF38AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PRPF38AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF38AP1 shows lower tumor expression in LIHC and CHOL and higher tumor expression in COAD and HNSC. The LIHC box plot shows higher PRPF38AP1 RNA expression in normal versus tumor tissue (log2 FC = −0.378, t-test p < 0.001).
This table shows molecular features associated with PRPF38AP1 in patient tissues and cancer cell lines. In patient samples, PRPF38AP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
